Brent Vaughan

Brent Vaughan

Auto-generated profile, based on publicly available information

Brent Vaughan

Cognito Therapeutics, Cambridge, MA USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Biochimie Open
Verified
Journal Article
Open access
PVPaula L. Vieira-Brock
Paula L. Vieira-Brock
BVBrent M. Vaughan
Brent M. Vaughan
DVDavid Vollmer
David Vollmer
Plant essential oils (EOs) are known to inhibit the growth of bacteria and fungi. Whether these antimicrobial effects are comparable to synthetic household products is less clear. Furthermore, limited research is available on the potential additive effect of blending EOs. In this investigation, a new EO blend containing orange, patchouli, peppermint, and clary sage was compared to its individual single oils and to three household products-air freshener, liquid soap, and body spray-for their ability to inhibit the growth of Staphylococcus aureus, Streptococcus pneumoniae, Pseudonomas aeruginosa, and Aspergillus brasiliensis in the disc-diffusion assay. The new EO blend significantly inhibited the growth of the four microorganisms. The zones of inhibition of new EO blend were greater than the air freshener and similar to the liquid soap and body spray, with the exception of Str. pneumoniae in which the body spray provided greater inhibitory zone. The new EO blend and the single oils, with the exception of peppermint, equally inhibited the growth of S. aureus and Str. pneumoniae suggesting no additive effect. P. aeruginosa and A. brasiliensis showed variable susceptibility to all EOs except for no susceptibility to orange and limonene. No difference was found between (-) and (+)-limonene; whereas, (+)-menthol showed greater effect than (-)-menthol. In conclusion, blending the EO of orange, patchouli, peppermint, and clary sage was beneficial in inhibiting the growth of S. aureus, Str. pneumoniae, P. aeruginosa, and A. brasiliensis providing a natural antimicrobial fragrance option over synthetics fragrances used in soaps, body sprays, and air fresheners.

1 January 2018
Verified
Journal Article
Open access
PVPaula de Lima Vieira-Brock
Paula de Lima Vieira-Brock
BVBrent M. Vaughan
Brent M. Vaughan
DVDavid L. Vollmer
David L. Vollmer
Background: Certain food ingredients promote thermogenesis and fat loss. Similarly, whey protein improves body composition. Due to this potential synergistic effect, a blend of thermogenic food ingredients containing African mango, citrus fruit extract, Coleus forskohlii, dihydrocapsiate, and red pepper was tested alone and in combination with a whey protein supplement for its effects on body composition in sedentary mice during high-fat diet. Objective: The objective of this study was to evaluate the interaction of thermogenic foods on improving body composition during consumption of an unhealthy diet. Materials and Methods: C57BL/6J young adult male mice (n = 12) were placed on a 60% high-fat diet for 4 weeks and subsequently randomly assigned to receive daily dosing by oral gavage of vehicle, the novel blend alone or with whey protein supplement for another 4 weeks. Body composition, thermal imaging of brown adipose tissue (BAT), mitochondrial BAT uncoupling protein 1 (UCP1), and plasma levels of leptin were assessed. Results: Novel blend alone and in combination with protein supplement attenuated body weight gain, fat, and increased surface BAT temperature in comparison to vehicle control and to baseline (P < 0.5). The combination of novel blend and whey protein supplement also significantly increased UCP1 protein expression in BAT mitochondria in comparison to vehicle control and novel blend alone (P < 0.5). Conclusions: These data indicate that this novel blend stimulates thermogenesis and attenuates the gain in body weight and fat in response to high-fat diet in mice and these effects were improved when administered in combination with whey protein supplement.

29 October 2021 in Journal of Immunological Methods
Verified
Journal Article
Open access
AAAnna Michele Andersen
Anna Michele Andersen
PVPaula L. Vieira-Brock
Paula L. Vieira-Brock
BVBrent Vaughan
Brent Vaughan
DVDavid Vollmer
David Vollmer
Background: Colostrum is the first milk that supplies newborns with immune supporting peptides. Due to its heterogeneous and variable characteristics, standardized assays for assessment of its biological activities are a challenge. The current set of studies were aimed to investigate the immune activity of bovine colostrum blends as well as develop a method to assess variability across different lots. Methods: Immune activity of a bovine colostrum blend was evaluated by their ability to enhance PBMC (peripheral blood mononuclear cell)-mediated killing of K562 cells. K562 cell killing was assessed by flow cytometry using DAPI. PBMCs derived from multiple healthy donors were initially investigated. Frozen PBMC aliquots from one of the highest responders were used for subsequent studies. Different doses and lots of product were assessed. Incubation time was also explored. Results: Bovine colostrum blend similarly reduced K562 cells number and these effects were often greater than the IL-2 positive control. Despite consistent efficacy at enhancing PBMCs-mediated K562 killing, the degree of the effect was significantly variable across different lots. These biological effects were largely dependent on the solubility of the product. Conclusion: Assessment of PBMC-mediated killing of K562 cells by flow cytometry using DAPI can be a reliable method for measuring immune activity of bovine colostrum when the material is well-dissolved into solution and the same biological sample from a single donor is used.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MHMihaly Hajos
Mihaly Hajos
ABAlyssa Boasso
Alyssa Boasso
ACAylin Cimenser
Aylin Cimenser
MSMonika Shpokayte
Monika Shpokayte
EHEvan Hempel
Evan Hempel
ZMZach Malchano
Zach Malchano
Background: Developing safe and disease modifying therapies for Alzheimer’s disease (AD) is still challenging, in spite of recent advancements in the understanding of AD pathophysiology. A fundamentally different therapeutic approach under development at Cognito Therapeutics targets abnormal neuronal activities using the company’s Gamma Sensory Stimulation System. This treatment is based on the recent breakthrough, demonstrating that 40Hz neuronal network oscillation evoked via optogenetic, or sensory stimulation profoundly reduces AD pathologies in AD‐related transgenic mice.Method: This presentation will provide an overview of the main findings from a clinical trial (NCT03556280) which evaluated Cognito Therapeutics Gamma Sensory Stimulation System as a potential novel therapeutic intervention for AD, evaluating feasibility, safety, tolerability, and efficacy of this treatment. In the 6‐month long, double‐blinded, randomized, controlled, clinical trial, participants with clinical presentation on the AD spectrum, were randomized 2:1 (active:sham) to receive daily, one‐hour 40Hz audio‐visual stimulation treatment using Cognito’s Gamma Sensory Stimulation System or sham stimulation.Result: A total of 135 subjects were screened, of whom 74 were randomized and 53 completed (20 sham arm, 33 active arm). Daily use of the Gamma Sensory Stimulation System was confirmed to be safe with minimal side effects. MRI data confirmed the absence of ARIA in participants. High adherence to daily therapy was established based on device‐recorded usage. In assessing cognitive and functional abilities, changes in ADCS‐ADL and MMSE scores were statistically significant between the sham and treatment arms, demonstrating a significant slowing in functional and cognitive decline in the treatment group. Further, quantitative MRI analysis revealed a significantly reduced whole brain, white matter, and occipital lobe volume loss, along with a significantly attenuated reduction in occipital cortical thickness in the active arm relative to sham. These clinical benefits were achieved independent of a reduction in amyloid plaque loads.Conclusion: Our results demonstrate that daily 40Hz sensory stimulation delivered by Cognito’s Gamma Sensory Stimulation System is safe and well tolerated; patients in the active arm maintained their functional and cognitive abilities, showed reduced brain atrophy. The upcoming pivotal clinical trial will further evaluate the clinical efficacy of this treatment, also evaluating its most relevant downstream mechanisms in AD patients.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ACAylin Cimenser
Aylin Cimenser
XDXiao Da
Xiao Da
EHEvan Hempel
Evan Hempel
ZMZach Malchano
Zach Malchano
BVBrent Vaughan
Brent Vaughan
MHMihaly Hajos
Mihaly Hajos
Background: Although morphometric changes in Alzheimer’s Disease (AD) occur both in gray and white matter, gray matter changes had been the primary focus of previous work. Recent studies have highlighted the importance of pathological changes in white matter and myelination in AD patients, including early changes to oligodendrocytes and transcription of myelin protein genes in the white matter prior to symptoms of cognitive decline, even in subjects with AD but without other neurological comorbidities (Ferrer et al., 2020). Since neuronal activities, particularly network oscillations have been shown to promote myelination, the present study examined how 40Hz gamma stimulation affected white matter volume and myelination in different cortical lobes in patients with AD.Method: Data were obtained from the Overture trial (NCT03555281) in which treatment participants received daily, at‐home, 40Hz gamma sensory stimulation for six months, while placebo participants received sham stimulation (treatment‐to‐placebo ratio 2:1). Magnetic resonance imaging (MRI) data were collected at 1.5 Tesla at baseline, month 3, and month 6. MRI T1 images and T1w/T2w ratios were used to estimate volume (N = 38) and myelination (N = 36), respectively. Using Bayesian linear mixed effects modeling, we estimated white matter volume and myelination percent changes with respect to baseline. Treatment group results were reported in relation to the placebo group.Result: With respect to the placebo group: In the left hemisphere, the treatment group exhibited reduced white matter atrophy in the frontal lobe (‐3.27±1.4, p = 0.0225), in the temporal lobe (‐3.9±1.76, p = 0.0306), in the parietal lobe (‐3.32±1.43, p = 0.0236), in the occipital lobe (‐4.1±1.72, p = 0.0195) and reduced demyelination in the frontal lobe (‐5.13±2.12, p = 0.0186), in the temporal lobe (‐5.33±2.42, p = 0.0321), in the parietal lobe (‐5.7±2.07 (p = 0.0079), in the occipital lobe (‐5.65±2.52, p = 0.0296). In the right hemisphere, the treatment group trended towards reduced white matter volume loss and demyelination in all lobes, however, demyelination was significantly reduced in the parietal lobe (‐4.48±2.09, p = 0.037), and in the occipital lobe (‐5.5±2.22, p = 0.0165).Conclusion: White matter atrophy and demyelination were statistically significantly reduced in all lobes of the left hemisphere and trended towards reduction in the right hemisphere, demonstrating that 40Hz sensory stimulation can reduce the neurodegeneration associated with AD.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
XDXiao Da
Xiao Da
EHEvan Hempel
Evan Hempel
ZMZach Malchano
Zach Malchano
BVBrent Vaughan
Brent Vaughan
JMJonathan Thomas Megerian
Jonathan Thomas Megerian
ACAylin Cimenser
Aylin Cimenser
Background: Previous research has shown that white matter (WM) and gray matter (GM) tissues exhibit regionally selective pathological changes in Alzheimer’s disease (AD). The contrast between WM and GM signal intensities (WM/GM contrast) measured by magnetic resonance imaging (MRI) has previously been proposed as a method for quantifying these changes. It has been shown that WM/GM contrast can provide sensitive, independent, and distinct information about pathologies compared with traditional MRI measures. Studies have also shown, including entorhinal WM/GM contrast to traditional MRI measures resulted in better discrimination between AD and controls. We previously demonstrated that 40Hz auditory‐visual stimulation therapy reduced WM atrophy and myelin loss in AD patients. The present study quantified the effects of the therapy on the WM/GM contrast in the entorhinal region.Method: This study used neuroimaging data from Overture, a phase I/II randomized, placebo‐controlled feasibility study (NCT03556280) in patients on the AD spectrum. Treatment group received 40Hz gamma sensory stimulation daily at home for six months, whereas placebo group received sham stimulation. Structural MRI was obtained at baseline, month 3 and month 6 visits using 1.5 Tesla scanner. FreeSurfer was used to process T1 MRI including entorhinal parcellation and cortical reconstructions for 38 participants (66% Treatment, 34% Placebo). For each vertex, WM signal intensity (WMI) is sampled at 1mm below, and GM signal intensity (GMI) is sampled at 30% of cortical thickness above the WM/GM border. WM/GM contrast was calculated as 100*(WMI–GMI)/(0.5*(WMI+GMI)) %. Bayesian linear mixed effects modeling was used to model changes in WM/GM contrast in the entorhinal region.Result: Following 6 months of treatment, we observed that the treatment group demonstrated 0.06±0.99% decrease and the placebo group demonstrated 1.26±1.04% decrease in WM/GM contrast (p<0.022).Conclusion: We found that six months of 40Hz gamma sensory therapy reduced the decline in WM/GM contrast in the entorhinal region. Since WM/GM contrast is associated with AD severity, and the entorhinal region is of particular interest in the early stages of AD, early intervention of the therapy may result in enhanced tissue preservation and reduced neurological damage.